Introduction
============

Brain development is a continuous process which extends from the prenatal period into adulthood ([@B51]). Abnormal neurodevelopmental processes are implicated in many psychiatric disorders such as schizophrenia, attention deficit hyperactivity disorder, autism spectrum disorder, and intellectual disability ([@B51]; [@B41]). Moreover, altered gene expression across different brain regions and lifespan has been reported in psychiatric disorders ([@B59]; [@B14]). For example, schizophrenia risk genes are reported to be associated with transcripts which are either enriched in specific brain regions or unique to the human brain, and some also show preferential expression in the fetal brain ([@B30]; [@B33]). Therefore, it is important to analyze the brain region-specific expression of risk genes for psychiatric disorders in the normal human brain across the lifespan to understand the mechanisms underlying pathological changes in psychiatric disorders.

[D]{.smallcaps}-amino acid oxidase (DAO/DAAO; from now on addressed as DAO) is a flavoenzyme, which oxidizes [D]{.smallcaps}-amino acids. Its main substrate in the brain is [D]{.smallcaps}-serine ([@B48]; [@B54]). [D]{.smallcaps}-serine is a co-agonist of *N*-methyl-[D]{.smallcaps}-aspartate (NMDA) receptors. In addition to glutamate, NMDA receptors require a co-agonist (glycine or [D]{.smallcaps}-serine) binding at the glycine modulatory site in order to function normally. [D]{.smallcaps}-serine is shown to be more potent in binding to NMDA receptors than glycine ([@B39]; [@B58]; [@B54]). Thus, DAO can regulate the function of NMDA receptors via [D]{.smallcaps}-serine breakdown, which may lead to NMDA receptor hypofunction ([@B31]; [@B36]; [@B62]; [@B37]). One of the possible explanations for NMDA receptor hypofunction theory proposed in schizophrenia is probably an increased activity of DAO leading to decreased [D]{.smallcaps}-serine. DAO activator (DAOA)/G72 (from now on addressed as DAOA) binds to DAO, but the effect of DAOA on DAO is controversial. This is because DAOA is reported to both increase ([@B12]; [@B10]) and decrease ([@B53], [@B55]) the activity of DAO. DAOA is localized in mitochondria and reported to modulate its function ([@B35]; [@B55]; [@B46]). Thus, the exact function of DAOA is not yet completely understood.

The human *DAO* gene located on chromosome 12q24 encodes for a ∼39 kDa protein ([@B2]; [@B53]; [@B62]) and the human *DAOA* gene encodes for a ∼20 kDa protein ([@B4]). The genes *DAOA*/*G30* overlap and are transcribed from opposite strands on chromosome 13q33. The polymorphisms of these genes in non-coding regions have been described to be associated with the pathophysiology of schizophrenia and bipolar disorder ([@B16]; [@B34]; [@B13]; [@B49]; [@B42]; [@B37]; [@B21]; [@B38]). However, a recent genome-wide association study conducted by the Psychiatric Genomics Consortium found that out of 108 schizophrenia-associated loci, none were within *DAO* and *DAOA* gene regions ([@B57]). There are several lines of evidence showing regional and cellular expression of DAO mRNA and protein in the human brain ([@B32]; [@B63]; [@B24]; [@B45]), however, none of these studies isolated mRNA and protein concomitantly from the same brain tissue as we did in this study. On the other hand, the reports of DAOA mRNA and protein expression in the human brain remain unconvincing to date. Studies showing *DAOA* mRNA expression in the human brain are limited ([@B12]; [@B34]). Moreover, the expression of DAOA mRNA and protein in the human brain has been questioned ([@B4]; [@B23]). The human protein atlas detected DAOA protein (also known as pLG72, from now on addressed as DAOA) in the cerebellum and the cerebral cortex ([@B61]). Thus, the regulation of DAO and DAOA expression in the human brain has not yet been elucidated.

Furthermore, since DNA methylation can lead to both increases and decreases in gene expression ([@B64]), it may play a crucial role in the regulation of normal brain development ([@B19]). [@B25] quantified DNA methylation using Illumina 450K array in normal human post-mortem brain, and reported that DNA methylation levels in cortical regions differ from the cerebellum. Moreover, epigenetic regulation of gene expression is very important in the human brain ([@B22]; [@B44]). However, the extent to which DNA methylation or other epigenetic modifications affect the expression of genes important for human brain function, such as *DAO*/*DAOA*, is largely unknown.

In the present study, our main aim was to understand concomitant DAO and DAOA mRNA and protein expression in the normal human post-mortem brain during development and aging in six brain regions. We also correlated *DAO* mRNA and DAO protein as well as DAO protein and DAOA protein to understand their concomitant expression in different brain regions. Furthermore, we assessed the potential effect of *DAO* and *DAOA* polymorphisms on DAO and DAOA expression levels to elucidate their role in the regulation of DAO and DAOA expression. To understand the hypothesized regulation of DAO and DAOA expression at the transcription level in an indirect manner, we determined the DNA methylation levels at CpG sites of *DAO* and *DAOA* genes in the cerebellum and the frontal cortex of control human post-mortem brain obtained from Gene Expression Omnibus (GEO) datasets.

Materials and Methods {#s1}
=====================

Subjects
--------

Human post-mortem brain samples from six brain regions were studied. These brain samples were from 55 subjects with age ranging from 16 weeks of gestation to 91 years, who had no history of psychiatric or neurological illness, and their post-mortem brain samples showed no neuropathological evidence of any neuropsychiatric disorder. The brain samples were collected from six brain regions, namely: the cerebellum (*n* = 47), brainstem (*n* = 49), amygdala (*n* = 47), striatum (*n* = 52), thalamus (*n* = 52), and frontal cortex (*n* = 54). These brain samples were procured from the Department of Neuropathology, Institute of Pathology, University of Würzburg, Germany (member of the BrainNet Europe-BNEII) and the London Neurodegenerative Diseases Brain Bank, UK. Informed written consent for tissue donation was obtained from the individuals or the next of kin. The causes of death of the study population are presented in Supplementary Table [S6](#SM1){ref-type="supplementary-material"}. This study was approved by the Cantonal Ethic Commission of Zurich (Ref. Nr. EK: KEK-ZH-Nr. 2013-0177).

DNA, RNA, and Protein Isolation
-------------------------------

DNA, RNA, and protein were simultaneously isolated from the same frozen human post-mortem brain samples using AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Switzerland). Firstly, frozen brain tissue samples weighing around 27--34 mg were disrupted and homogenized in the buffer provided in the kit using the TissueLyser II (Qiagen, Switzerland). Secondly, tissue lysates were added to the AllPrep DNA spin column, and DNA was eluted. Thirdly, RNA was eluted after adding an ethanol treated sample to a RNeasy spin column. Finally, proteins in the sample were precipitated and pelleted by centrifugation. Since the buffer provided in the kit interferes with protein determination and does not dissolve proteins completely, protein eluates were acetone precipitated, and precipitated proteins were redissolved in urea buffer (7 M urea, 2 M thiourea, 2% CHAPS, and trace bromophenol, pH 8).

TaqMan SNP Genotyping
---------------------

DNA isolated from post-mortem human cerebellum (*n* = 46), striatum (*n* = 2), thalamus (*n* = 5), and amygdala (*n* = 2) were used for genotyping. DNA concentrations, A260/A280, and A260/A230 ratios were measured using a spectrophotometer (NanoVue Plus, GE Healthcare Life Sciences). Real-time polymerase chain reaction (PCR) was used to genotype *DAO* (rs3918347, rs4623951), and *DAOA* (rs778293, rs3916971, rs746187) polymorphisms. These single-nucleotide polymorphisms (SNPs) were chosen based on previously reported association with schizophrenia ([@B1]). DNA, TaqMan^^®^^ Genotyping Master Mix (Applied Biosystems, USA), and SNP Genotyping Assays (rs778293 assay number: C_8704507_10; rs3916971 assay number: C_27495752_10; rs746187 assay number: C_1925241_10; rs3918347 assay number: C_27937201_10; and rs4623951 assay number: C_32177440_10, all from Applied Biosystems, USA) were combined in a 384-well plate. Real-time PCR was performed in a C1000^TM^ CFX384^TM^ Thermal cycler (Bio-Rad) using TaqMan^^®^^ SNP Genotyping Assay PCR standard protocol. Genotypes were determined by the allelic discrimination program of Bio-Rad CFX Manager^TM^ Software version 2.1. The Hardy--Weinberg equilibrium (HWE) *p*-value and allele frequencies were computed using PLINK software ([@B50]), and *p* \< 0.05 was considered as statistically significant.

Quantification of *DAO* and *DAOA* mRNA Levels Using qRT-PCR
------------------------------------------------------------

RNA isolated from post-mortem human cerebellum (*n* = 44), brainstem (*n* = 40), amygdala (*n* = 39), striatum (*n* = 35), thalamus (*n* = 37), and frontal cortex (*n* = 36) were used for quantitative real-time reverse transcription-PCR (qRT-PCR). A spectrophotometer (NanoVue Plus, GE Healthcare Life Sciences) was used to measure RNA concentrations, A260/A280, and A260/A230 ratios. RNA integrity was analyzed using Experion automated electrophoresis system (Bio-Rad, Switzerland) in a subset of samples. RNA (500 ng) was reverse transcribed using iScript^TM^ cDNA Synthesis Kit (Bio-Rad, Switzerland) as per manufacturer's protocol. In a subset of samples, negative controls were prepared with RNA without reverse transcriptase enzyme. qRT-PCR was performed using cDNA, QuantiFast SYBR Green PCR kit (Qiagen, Switzerland), 1 μM forward and reverse DAO primers (Microsynth, Switzerland), and reference genes \[β-actin (*ACTB*) (QT01680476), aminolevulinate synthetase (*ALAS1*) (QT00073122), ribosomal protein L13a (*RPL13A*) (QT00089915), alanyl-tRNA synthetase (*AARS*) (QT00054747), glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) (QT01192646), peptidylprolyl isomerase A (*PPIA*) (QT00866137), ribosomal RNA (*R18S*) (QT00019936), and X-prolyl aminopeptidase 1 (*XPNPEP1*) (QT00051471); all from Qiagen, Switzerland\]. These eight reference genes were selected based on previous reports of their stability in human post-mortem brain ([@B17]). The DAO primers used in this study have been described by [@B63] (forward primer: CGCAGACGTGATTGTCAACT; reverse primer: GGATGATGTACGGGGAATTG). *DAO* mRNA levels were normalized to the reference genes. PCR efficiencies were calculated using LinRegPCR program ([@B52]) and mean PCR efficiencies for all studied amplicons were found to be between 88 and 95%. Normalized *DAO* mRNA levels were quantified by importing qRT-PCR quantification cycle (Cq) values of the gene of interest and reference genes across brain regions and lifespan into qBASE plus software (Biogazelle, Belgium) which utilizes gene-specific amplification efficiencies, and allows normalization with multiple reference genes. The qBASE plus software automatically selects multiple stably expressed reference genes in the samples across brain regions and lifespan by taking into account their stability. The software carries out a normalization of the gene of interest with multiple reference genes, ultimately producing calibrated normalized relative quantities of the gene of interest which was used to perform statistical analysis ([@B26]). To detect *DAOA* mRNA in human post-mortem brain, qRT-PCR was performed using several different primers for *DAOA* gene described by [@B4], [@B11], and pre-designed primers \[QT00058863 (Qiagen), Hs.PT.58.555086 (IDT), 4331182 (Thermo Fisher Scientific), qHsaCEP0024792 (Bio-Rad)\]. As a positive control, these primers were also tested on the cDNA prepared from human neuroblastoma cells (SK-N-SH and SH-SY5Y) overexpressing DAOA, and these primers detected *DAOA* mRNA in these cells, but not in the human post-mortem brain samples (data not shown). *DAOA* mRNA was still undetectable in human post-mortem brain after increasing the cDNA amounts in qRT-PCR. Furthermore, amplification using QuantiTect Whole Transcriptome Kit (207043, Qiagen) followed by qRT-PCR to detect *DAOA* mRNA levels was not successful. In summary, we were unable to quantify *DAOA* mRNA levels with any of the aforementioned methods in human post-mortem brain.

Quantification of DAO and DAOA Protein Levels Using Commercially Available ELISA Kits
-------------------------------------------------------------------------------------

Protein isolated and acetone-precipitated from post-mortem human cerebellum (*n* = 40), brainstem (*n* = 47), amygdala (*n* = 46), striatum (*n* = 48), thalamus (*n* = 48), and frontal cortex (*n* = 54) were used for enzyme-linked immunosorbent assay (ELISA). Total protein concentration was quantified using the Bradford assay (Sigma-Aldrich; [@B6]). DAO and DAOA protein concentrations were quantified using a commercially available DAO ELISA kit (SEJ298Hu; Cloud-Clone Corp.) with a high specificity and a sensitivity of 0.56 ng/mL and a commercially available DAOA ELISA kit (SEJ297Hu; Cloud-Clone Corp.) with a high specificity and a sensitivity of 0.061 ng/mL according to the manufacturer's instructions. A standard curve was obtained by plotting absorbance versus different concentration of protein standards provided with the kit, and DAO and DAOA protein concentrations were determined from the standard curve. Normalized DAO and DAOA protein concentrations were calculated by dividing DAO and DAOA protein concentrations by the total protein concentration measured using Bradford assay. The specificity of DAO and DAOA ELISA kits was proved using sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blotting which is described in detail in Supplementary Methods [S1](#SM1){ref-type="supplementary-material"}.

DNA Methylation Levels across *DAO* and *DAOA* CpG Sites in the Cerebellum and Frontal Cortex
---------------------------------------------------------------------------------------------

The processed and normalized methylation beta values from two datasets: GEO accession number [GSE61431](GSE61431) as described in the study of [@B47] and GSE63347 as described by [@B27] were downloaded from the GEO website^[1](#fn01){ref-type="fn"}^. From these datasets, the methylation beta values for *DAO* and *DAOA* CpG sites from the cerebellum and frontal cortex of controls were extracted. *DAO* (cg03868278, cg22621535, cg22801690) and *DAOA* (cg00809502) CpG sites in the repeat masker region sites were excluded from the analysis. *DAO* CpG sites: cg01694331, cg25362648, cg18037826, cg12592321 lie in the exon 1 and cg26725638 in the exon 2 of *DAO* gene. *DAOA* CpG sites: cg22773522, cg25623522, cg01297020 are in the promoter region, cg13846327 and cg20888753 in the intron 2, and cg11374446 in the intron 3 region of the *DAOA* gene. In the GSE61431 dataset, there were 23 control cerebellum and frontal cortex samples ranging from ages 25 to 96 years. In the GSE63347 dataset, there were nine control cerebellum samples in the ages between 38 and 64 years and 17 control frontal cortex samples between ages 32 and 64 years.

Statistical Analysis
--------------------

IBM^^®^^ SPSS^^®^^ Statistics (version 21) software was used for statistical analysis. Shapiro--Wilk test with Lilliefors significance correction was used to assess the normality of the distribution of mRNA, protein expression, and DNA methylation data. *DAO* mRNA, DAO and DAOA protein expression, and DNA methylation data showed both normal and non-normal distribution across different brain regions. In order to maintain consistency between statistical evaluations, non-parametric tests were used even for normally distributed data. Linear regression with brain regions as dummy variables was used after a logarithmic transformation of the non-normally distributed data to determine the differences in *DAO* mRNA, DAO and DAOA protein expression in the brain regions studied; *p* \< 0.05 was taken as statistically significant. The differences in *DAO* mRNA, and DAO and DAOA protein levels across different age groups were assessed by the Kruskal--Wallis test followed by pair-wise comparisons with the Mann--Whitney test by adjusting *p*-value based on the number of comparisons (Bonferroni correction, *p* \< 0.005). As we do not have post-mortem brain samples from ages 2 to 20 years, we divided the ages for correlation into two groups, namely less than 2 years and more than 20 years. Then, Spearman's rank correlation test was used to assess the correlation between age groups (\<2 years and \>20 years) and *DAO* mRNA, DAO and DAOA protein levels; *p* \< 0.05 was taken as statistically significant. We correlated *DAO* mRNA with DAO protein levels, and DAO protein levels with DAOA protein levels across six brain regions by controlling for age using partial correlation, *p* \< 0.05 was taken as statistically significant. To analyze the effect of *DAO* and *DAOA* SNP genotypes on *DAO* mRNA, DAO and DAOA protein expression, analysis of covariance (ANCOVA) with age as a covariate was used after a logarithmic transformation of not normally distributed *DAO* mRNA and DAOA protein expression data and the inverse transformation of the non-normally distributed DAO protein expression data; *p* \< 0.05 was taken as statistically significant. The differences in methylation levels between the cerebellum and frontal cortex at each CpG site was assessed using the Mann--Whitney test by adjusting *p*-value based on a number of CpG sites analyzed (Bonferroni correction, *p* \< 0.005). The correlation between age and methylation levels at each CpG site in the cerebellum and frontal cortex was assessed using Spearman's rank correlation test, and *p* \< 0.05 was considered statistically significant. GraphPad Prism software (version 6.01) was used to plot the graphs. The *post hoc* power analyses for *DAO* mRNA, DAO and DAOA protein expression across five age groups were conducted using G\*Power software ([@B20]), the effect sizes were determined from means of age groups, and the alpha level was set at 0.05 (Supplementary Table [S7](#SM1){ref-type="supplementary-material"}).

Results
=======

DAO and DAOA Expression in Different Brain Regions
--------------------------------------------------

The current study aimed to assess brain region-specific DAO and DAOA expression across the lifespan in normal human post-mortem brain using qRT-PCR and ELISA techniques. The human post-mortem brain samples were obtained from 55 subjects with no clinical or neuropathological evidence of neuropsychiatric disorders. The demographic characteristics of the study sample across five age groups are presented in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}. In order to assess any confounding factors inherent in human post-mortem studies, we addressed factors such as post-mortem interval (PMI) and gender. The length of PMI did not differ significantly between different age groups as assessed by the Kruskal--Wallis test. Gender had a significant effect on *DAO* mRNA (*p* = 0.048) and protein (*p* = 0.047) expression in the thalamus and frontal cortex, respectively (Mann--Whitney test, *p* \< 0.05). *DAO* mRNA in the thalamus and DAO protein in the frontal cortex was significantly more expressed in males than in females. Gender had no significant effect on DAOA protein expression in all brain areas studied. There was no statistically significant correlation between PMI and *DAO* mRNA, DAO and DAOA protein levels in the studied brain regions (Spearman's rank correlation, *p* \> 0.05).

With the aim of investigating brain region-specific patterns of DAO and DAOA, we assessed their expression in the normal brain. We found that *DAO* mRNA was significantly more expressed in the cerebellum (set to 100%), followed by the brainstem (17.6%), thalamus (4.8%), striatum (2.5%), amygdala (0.9%), and the frontal cortex (0.7%) as assessed by linear regression (**Figures [1A,B](#F1){ref-type="fig"}**). In contrast to *DAO* mRNA, DAO protein was significantly less expressed in the cerebellum than in the remaining brain regions. In the amygdala (set to 100%), DAO protein was significantly more expressed than in the brainstem (79.2%; **Figure [1C](#F1){ref-type="fig"}**). DAOA protein was significantly more expressed in the frontal cortex (set to 100%) than in the cerebellum (65.2%), amygdala (80.4%), and the thalamus (69.6%). In the striatum (set to 100%), DAOA protein was significantly more expressed than in the amygdala (66.7%) and the cerebellum (54.1%). DAOA protein was significantly less expressed in the thalamus (57.7%) than in the brainstem (85.6%) and striatum (set to 100%; **Figure [1D](#F1){ref-type="fig"}**). Thus, DAO and DAOA exhibit region-specific expression patterns in the human brain.

![***DAO* mRNA, DAO and DAOA protein levels quantified in six regions of human post-mortem brain. (A)** Normalized *DAO* mRNA levels across six brain regions. **(B)** For clarity, this figure focuses only on amygdala, striatum, thalamus, and frontal cortex results presented in panel **(A)**. DAO protein levels (μg DAO/mg total protein) **(C)** and DAOA protein levels (μg DAOA/mg total protein) **(D)** in studied brain regions. Values are presented as box and whisker plots, whiskers represent minimum to maximum values, "+" indicates mean values, and ^∗^*p* \< 0.05. Linear regression with brain regions as dummy variables was used after logarithmic transformation of non-normally distributed data.](fnana-11-00031-g001){#F1}

Expression of *DAO* mRNA, DAO and DAOA Protein across Lifespan in Six Brain Regions
-----------------------------------------------------------------------------------

The expression patterns across lifespan were analyzed using two approaches. The first approach was by grouping ages into five groups, while the second approach was by correlating ages with expression levels which provided information on expression patterns during brain development, maturation, and degeneration. We assessed DAO and DAOA expression across age groups in six brain regions to understand critical and sensitive periods during brain development. As the sample size in each age group was small, we performed a power analysis which showed reasonable power (\>0.76) in the cerebellum, striatum, and thalamus for *DAO* mRNA as well as reasonable power (\>0.64) in the cerebellum, striatum, and frontal cortex for DAO protein, but the power was too low in the brain regions studied for DAOA protein to conduct statistical analysis (Supplementary Table [S7](#SM1){ref-type="supplementary-material"}).

We found statistically significant (*p* \< 0.05) differences in *DAO* mRNA levels across the five different age groups, as assessed by the Kruskal--Wallis test, in the cerebellum, brainstem (**Figure [2B](#F2){ref-type="fig"}**), amygdala, striatum, and thalamus. However, differences in *DAO* mRNA levels were found to be statistically non-significant in the frontal cortex (**Figure [2F](#F2){ref-type="fig"}**). Pair-wise comparisons using the Mann--Whitney test showed statistically significant differences (*p* \< 0.005) in *DAO* mRNA levels between age groups 0--2 years and \>61 years in the cerebellum (**Figure [2A](#F2){ref-type="fig"}**) and striatum (**Figure [2D](#F2){ref-type="fig"}**), between prenatal and \>61 years in the amygdala (**Figure [2C](#F2){ref-type="fig"}**), and between prenatal and \>61 years, 0--2 years and 36--60 years, 0--2 years and \>61 years in the thalamus (**Figure [2E](#F2){ref-type="fig"}**).

![***DAO* mRNA levels across five different age groups in six regions of human post-mortem brain (A--F).** Data presented as scatter plots. Kruskal--Wallis test followed by pairwise comparisons with the Mann--Whitney test (^∗^*p* \< 0.005) was performed to assess the differences in *DAO* mRNA levels between different age groups across six brain regions.](fnana-11-00031-g002){#F2}

The differences in DAO protein levels across the five different age groups was found to be statistically significant (*p* \< 0.05), as assessed by the Kruskal--Wallis test, in the cerebellum (**Figure [3A](#F3){ref-type="fig"}**), striatum (**Figure [3D](#F3){ref-type="fig"}**), and frontal cortex (**Figure [3F](#F3){ref-type="fig"}**). However, differences in DAO protein levels were found to be statistically non-significant in the brainstem (**Figure [3B](#F3){ref-type="fig"}**), amygdala (**Figure [3C](#F3){ref-type="fig"}**), and thalamus (**Figure [3E](#F3){ref-type="fig"}**). Pair-wise comparisons with the Mann--Whitney test showed statistically significant differences (*p* \< 0.005) in DAO protein levels for age groups \>61 years versus prenatal and 0--2 years in the frontal cortex (**Figure [3F](#F3){ref-type="fig"}**). The differences in DAOA protein levels across the five different age groups were found to be statistically significant (*p* \< 0.05) in the brainstem as assessed by the Kruskal--Wallis test. There were no statistically significant differences in DAOA protein levels in the cerebellum, amygdala, striatum, thalamus, and frontal cortex (**Figure [4](#F4){ref-type="fig"}**). The specificity of DAO and DAOA ELISA kits was demonstrated by Western blot as presented in Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}.

![**DAO protein levels (μg DAO/mg total protein) across different age groups in six regions of human post-mortem brain (A--F).** Data presented as scatter plots. Differences in DAO protein levels across different age groups was assessed by the Kruskal--Wallis test followed by pairwise comparisons with the Mann--Whitney test (^∗^*p* \< 0.005).](fnana-11-00031-g003){#F3}

![**DAOA protein expression (μg DAOA/mg total protein) across five different age groups in six regions of human post-mortem brain (A--F).** Values are presented as scatter plots. Differences in DAOA protein levels across different age groups were assessed with the Kruskal--Wallis test.](fnana-11-00031-g004){#F4}

Using the second approach, we correlated age (\<2 years and \>20 years) with DAO and DAOA expression across different brain regions to understand the critical developmental period and brain region in DAO and DAOA expression. We found a statistically significant positive correlation (*p* \< 0.05) as assessed by Spearman's rank correlation test, between age less than 2 years and *DAO* mRNA levels in the cerebellum and amygdala (**Table [1](#T1){ref-type="table"}**). Furthermore, there was a significant positive correlation (Spearman's rank correlation, *p* \< 0.01) between age more than 20 years and DAO protein concentration in the frontal cortex (**Table [1](#T1){ref-type="table"}**). There was no statistically significant correlation between age and DAOA protein concentration in the brain regions studied (**Table [1](#T1){ref-type="table"}**).

###### 

Correlation between age and *DAO* mRNA, DAO and DAOA protein expression across brain regions of human post-mortem brain.

                                                                   Brain regions    Age in years                                      
  ---------------------------------------------------------------- ---------------- -------------- -------- ----------- ---- -------- ----------
  Normalized *DAO* mRNA levels                                     Cerebellum       12             0.828    0.001^∗∗^   32   0.127    0.488
                                                                   Brainstem        11             0.310    0.354       29   0.117    0.546
                                                                   Amygdala         13             0.669    0.017^∗^    26   0.261    0.198
                                                                   Striatum         9              0.008    0.983       26   0.259    0.202
                                                                   Thalamus         10             0.427    0.218       27   0.254    0.200
                                                                   Frontal cortex   11             0.352    0.288       25   0.022    0.918
                                                                                                                                      
  Relative DAO protein concentration (μg DAO/mg total protein)     Cerebellum       12             -0.495   0.102       27   -0.143   0.478
                                                                   Brainstem        16             0.092    0.736       31   0.077    0.679
                                                                   Amygdala         16             -0.122   0.652       30   0.162    0.392
                                                                   Striatum         18             0.082    0.747       30   0.142    0.455
                                                                   Thalamus         20             0.285    0.224       28   0.180    0.359
                                                                   Frontal cortex   21             0.185    0.422       33   0.482    0.004^∗^
                                                                                                                                      
  Relative DAOA protein concentration (μg DAOA/mg total protein)   Cerebellum       13             0.120    0.695       27   0.099    0.623
                                                                   Brainstem        16             0.332    0.210       30   0.324    0.081
                                                                   Amygdala         13             0.318    0.268       26   0.306    0.121
                                                                   Striatum         19             0.037    0.879       29   -0.120   0.536
                                                                   Thalamus         20             0.195    0.411       27   0.021    0.916
                                                                   Frontal cortex   20             -0.200   0.398       32   0.149    0.417

∗

p \< 0.05;

∗∗

p

\< 0.01

.

Correlation between *DAO* mRNA, DAO and DAOA Protein in Different Brain Regions
-------------------------------------------------------------------------------

In order to assess whether there is a concomitant expression of *DAO* mRNA and its protein, we correlated the two in various brain regions. We did not find any statistically significant correlation (partial correlation controlled for age) between *DAO* mRNA and DAO protein in each of the studied brain regions (Supplementary Figure [S3](#SM1){ref-type="supplementary-material"}).

As we concomitantly measured DAO and DAOA proteins in the human brain, we examined whether these two proteins correlate in each brain region. A statistically significant positive correlation (partial correlation controlled for age) was found between DAO and DAOA protein expression in the cerebellum \[*r*(36) = 0.74, *p* \< 0.0001; **Figure [5A](#F5){ref-type="fig"}**\], the brainstem \[*r*(43) = 0.84, *p* \< 0.0001; **Figure [5B](#F5){ref-type="fig"}**\], the amygdala \[*r*(36) = 0.88, *p* \< 0.0001; **Figure [5C](#F5){ref-type="fig"}**\], the striatum \[*r*(43) = 0.84, *p* \< 0.0001; **Figure [5D](#F5){ref-type="fig"}**\], and the thalamus \[*r*(44) = 0.91, *p* \< 0.0001; **Figure [5E](#F5){ref-type="fig"}**\]. However, there was no statistically significant correlation between DAO and DAOA protein concentration in the frontal cortex \[*r*(49) = 0.27, *p* = 0.06; **Figure [5F](#F5){ref-type="fig"}**\].

![**Correlation between DAO (μg DAO/mg total protein) and DAOA protein expression (μg DAOA/mg total protein) in six regions of the human post-mortem brain (A--F).** Data is presented as scatter plots with linear fit and 95% confidence intervals. Correlation between DAO and DAOA protein levels in different brain regions were assessed with the partial correlation test, controlled for age; *p* \< 0.05 was taken as statistically significant (*N*: sample size, *r*: correlation co-efficient).](fnana-11-00031-g005){#F5}

DAO and DAOA Expression across *DAO* and *DAOA* SNP Genotypes in Different Brain Regions
----------------------------------------------------------------------------------------

We assessed the potential effect of *DAO* and *DAOA* SNPs on DAO and DAOA expression to understand whether such genetic variations known to be risk factors in schizophrenia play a role in the regulation of their expression. The *DAO* and *DAOA* SNPs were in HWE (*p* \> 0.05), and the minor allele frequency (MAF) of *DAO* and *DAOA* SNPs were similar to HapMap CEU MAF (Supplementary Table [S2](#SM1){ref-type="supplementary-material"}). In the thalamus, *DAO* mRNA was significantly more expressed in rs3918347 *DAO* genotype GG (minor allele G) than in rs3918347 *DAO* genotypes (GA, AA), and *DAO* mRNA was less expressed in rs3918347 *DAO* genotypes GG + GA than in rs3918347 *DAO* genotype AA as assessed by ANCOVA with age as covariate (Supplementary Table [S3](#SM1){ref-type="supplementary-material"}). However, for the DAO protein, no statistically significant difference was detected among rs3918347 and rs4623951 *DAO* genotypes (Supplementary Table [S4](#SM1){ref-type="supplementary-material"}). For DAOA protein expression, there was a significantly higher expression in rs3916971 *DAOA* genotype TT (minor allele T) than in rs3916971 *DAOA* genotypes (CT, CC, CT + CC) in the amygdala, as assessed by ANCOVA with age as a covariate (Supplementary Table [S5](#SM1){ref-type="supplementary-material"}). Nonetheless, from our findings, we cannot conclusively comment on the effect of *DAO* and *DAOA* SNPs on their expression due to their rather small sample size.

DNA Methylation across *DAO* and *DAOA* CpG Sites in Cerebellum and Frontal Cortex
----------------------------------------------------------------------------------

From our DAO and DAOA mRNA and protein findings, we hypothesized a possible regulation of their expression at the transcriptional levels. To elucidate this, we analyzed *in silico* DNA methylation across *DAO* and *DAOA* CpG sites in the cerebellum and frontal cortex to indirectly explain the differential DAO and DAOA expression in the human brain. In GSE61431 and GSE63347 datasets, gender had no statistically significant effect on DNA methylation levels at *DAO* and *DAOA* CpG sites in the cerebellum and frontal cortex (Mann--Whitney test, *p* \> 0.005). In GSE61431 and GSE63347 datasets, *DAO* CpG site cg18037826 is significantly more methylated in the cerebellum than in the frontal cortex as assessed by the Mann--Whitney test, *p* \< 0.001 (Supplementary Figure [S1A](#SM1){ref-type="supplementary-material"}). In the GSE61431 dataset, all studied *DAOA* CpG sites except cg13846327 are statistically significantly (*p* \< 0.001) more methylated in the cerebellum than in the frontal cortex (Supplementary Figure [S1B](#SM1){ref-type="supplementary-material"}). In GSE63347 dataset, *DAOA* CpG sites cg22773522, cg20888753, and cg11374446 are significantly more methylated in the cerebellum than in the frontal cortex (Supplementary Figure [S1B](#SM1){ref-type="supplementary-material"}). There was no statistically significant correlation between age and DNA methylation levels at *DAO* and *DAOA* CpG sites in the cerebellum and frontal cortex in both studied datasets.

Discussion
==========

This study investigated the age-span expression of DAO and DAOA mRNA and protein in six brain regions of normal human post-mortem brain samples. In this study, we also determined *in silico* DNA methylation levels at *DAO* and *DAOA* CpG sites in the cerebellum and frontal cortex of control human post-mortem brain. The results of this study have implications for understanding the regulation and expression of *DAO* and *DAOA* genes in the normal human brain during development and aging.

In this study, DAO mRNA and protein was detected in all brain regions studied. *DAO* mRNA was highly expressed in the cerebellum as compared to the other brain regions studied. This finding is in line with previous studies of DAO expression in the human brain ([@B32]; [@B63]; [@B23]). This is the first study which quantified DAO protein in human post-mortem brain using the quantitative ELISA method. Previous studies detected DAO protein in the human brain using methods such as immunohistochemistry and Western blot ([@B3]; [@B63]; [@B61]). Immunohistochemical studies measured DAO immunoreactivity in the human brain and found that DAO protein was robustly detected both in the cerebellum and cerebral cortex ([@B63]; [@B61]). Another study detected DAO protein in the frontal cortex and hippocampus using Western blot ([@B3]). We found that DAO protein was less expressed in the cerebellum, but *DAO* mRNA was highly expressed in the cerebellum as compared to other regions studied, which might indicate post-transcriptional regulation such as microRNA (miRNA) mediated regulation. The miRWalk 2.0 database ([@B18]) with prediction algorithms from four different databases (miRWalk, miRanda, RNA22, Targetscan) showed that there are around 327 predicted miRNA target sites in the promoter region (miRWalk, miRanda, Targetscan), three predicted miRNA target sites in the 5′UTR (miRWalk, miRanda, RNA22), 74 predicted miRNA target sites in the coding DNA sequence (CDS) (miRWalk, miRanda, RNA22, Targetscan), and nine predicted miRNA target sites in the 3′UTR (miRWalk, miRanda, RNA22, Targetscan) of the *DAO* gene. The interaction of these miRNAs with the *DAO* gene in the cerebellum might be the reason for more *DAO* mRNA and less DAO protein. However, these interactions have to be confirmed experimentally. We measured DAO protein but not the activity of DAO protein because the buffer used to isolate proteins deactivated the DAO enzyme. Therefore, in our study, we are unable to comment on the activity of DAO in different brain regions. The DAO protein can be either in an active \[flavin adenine dinucleotide (FAD bound) or inactive (FAD unbound) state; [@B8]; [@B60]\]. [@B32] showed that DAO activity was detected in the human cerebellum but not in the human forebrain. Moreover, a recent study by [@B56] showed that DAO activity was detected in the human hindbrain, midbrain, spinal cord, and only in the white matter of the forebrain. Therefore, DAO activity in the human forebrain is not yet very clear.

*DAOA* is a primate-specific gene which shows a complex alternative splicing pattern, and encodes a protein characterized by a rapidly changing structure during evolution ([@B12]). The DAOA gene and protein expression in the human brain have not yet been fully characterized. We detected DAOA protein using ELISA in all of the brain regions studied. The human protein atlas detected DAOA protein in the cerebellum and cerebral cortex using immunohistochemistry ([@B61]). [@B35] detected DAOA protein in the human amygdala using Western blot. However, [@B4] could not detect DAOA protein in the human brain (cerebellum, amygdala, frontal cortex) using Western blot. Studies showing *DAOA* mRNA expression in the human brain are limited ([@B12]; [@B34]). We were unable to detect *DAOA* mRNA in all the brain regions studied using qRT-PCR, which is in line with previous studies that used methods such as northern blotting, qRT-PCR, and RNA sequencing ([@B4]; [@B23]). The reason for detecting DAOA protein but not *DAOA* mRNA in the human brain might be a tightly regulated DAOA expression or extremely localized expression or post-transcriptional regulation by RNA methylation. A previous study suggested that undetectable *DAOA* mRNA in the human brain might be because of RNA instability motif found in the 5′UTR of *DAOA* gene ([@B4]). There are around 314 predicted miRNA target sites in the promoter region (miRWalk, miRanda, Targetscan), five predicted miRNA target sites in the 5′UTR (miRWalk, miRanda, RNA22), 317 predicted miRNA target sites in the CDS (miRWalk, miRanda, Targetscan), and 70 predicted miRNA target sites in the 3′UTR (miRWalk, miRanda, RNA22) of the *DAOA* gene as described in the miRWalk 2.0 database ([@B18]) with prediction algorithms from four different databases (miRWalk, miRanda, RNA22, Targetscan). The interaction of these miRNAs with the *DAOA* gene might be the reason for the variation of DAOA protein expression in different brain regions. However, the interactions of miRNA with the *DAOA* gene have to be confirmed experimentally.

During brain development, there are critical and sensitive periods during which the brain is more vulnerable to environmental insults that can potentially lead to psychiatric disorders ([@B40]). In order to understand pathological changes that occur in psychiatric disorders, it is important to analyze the expression of risk genes for psychiatric disorders in the normal brain across the lifespan. In our study, we found that *DAO* mRNA levels were positively correlated with age less than 2 years in the cerebellum and amygdala. Our data is in agreement with previous studies of whole-genome expression analysis in the developing brain which reported that prenatal and neonatal periods are associated with a rapid change of gene expression patterns in the brain as compared to other age periods ([@B30]; [@B43]). During brain development and maturation, synaptic plasticity varies significantly across different brain regions, which might contribute to the brain region-specific gene expression ([@B28]; [@B9]). In this study, DAO expression was brain region specific, indicating that DAO is differentially regulated across hindbrain and forebrain regions. Interestingly, we found a significant positive correlation between DAO and DAOA protein in all the brain regions studied except for the frontal cortex. This positive correlation between DAO and DAOA protein might be because of the variability in density of particular cell types in different brain regions. A recent *in vitro* study showed that there is an interaction between DAO and DAOA proteins ([@B5]). Nonetheless, the effect of DAOA protein on DAO is controversial. [@B12] reported DAOA to be an activator of DAO, but [@B53] reported DAOA to be a repressor of DAO. From our finding, we are still unable to conclude regarding DAO and DAOA interaction, but we could show their simultaneous expression.

DNA methylation has been widely acknowledged to be crucial for normal brain development ([@B19]), and alterations in DNA methylome in the human brain might contribute to neuropsychiatric disorders ([@B29]). DNA methylation can lead to both increases and decreases in gene expression ([@B64]). We found *in silico* that the cerebellum was significantly more methylated than the frontal cortex in most of the *DAO* and *DAOA* CpG sites which is in line with previous studies ([@B15]; [@B25]; [@B29]). This finding might explain the differential expression of *DAO* mRNA in the cerebellum and frontal cortex. However, further studies are required to understand the extent to which DNA methylation or other epigenetic modifications affect the expression of genes important for human brain function.

In this study, we attempted to carefully address confounding factors such as PMI and gender that are inherent in human post-mortem studies. Our study is the first study which measured concomitantly DAO and DAOA protein levels in human post-mortem brain using quantitative ELISA method. Nevertheless, we were only able to measure total DAO protein but not the DAO activity in different brain regions because of the isolation procedure used. In our study, we had no post-mortem samples between ages 2 and 20 years, therefore we are unable to comment on alterations within this particular developmental phase. We also do not have schizophrenia brain samples to comment on regulation and expression of DAO and DAOA mRNA and protein across different brain regions in schizophrenia. *DAO* and *DAOA* are susceptibility genes for schizophrenia and bipolar disorders. Both disorders are discussed as neurodevelopmental disorders, and first symptoms often occur before early adulthood, whereas the definitive onset of the disorder is typically in early adulthood ([@B7]; [@B51]). Therefore, it is important to investigate the regulation of these genes between 2 and 20 years in the normal human brain. Hence, future studies in this age period would be useful to elucidate this question. Another limitation of the study is that because of limited sample size, it is not powered appropriately, particularly regarding the effect of *DAO* and *DAOA* polymorphisms on their expression. However, the strength of this study lies in the fact that we extracted DNA, RNA, and total protein from the same tissue, which allowed us to investigate concomitantly DAO and DAOA expression in six different brain regions and across a wide range of ages.

In summary, our results showed the regional expression of DAO and DAOA with age in normal human post-mortem brain samples. We detected DAOA protein, despite undetectable *DAOA* mRNA levels in the human post-mortem brain.
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